Skip to main content
. 2022 Jan 25;79(3):223–233. doi: 10.1016/j.jacc.2021.10.044

Figure 3.

Figure 3

Effect of Lp(a) on Plaque Progression

Data are depicted as betas with 95% CIs for the percentage change in plaque volume from baseline to follow-up CCTA, standardized for each 50 mg/dL increase in Lp(a). Lp(a) was associated with low-attenuation plaque progression in univariable (β = 10.2%, P = 0.031) and multivariable (β = 9.6%, P = 0.048) analyses, and with fibro-fatty plaque progression in univariable analysis (β = 6.7%, P = 0.034), showing a trend in multivariable analysis (β = 6.0%, P = 0.062). Abbreviations as in Figure 1.